HQL abrdn Life Sciences Investors Insider Trading

Director Pittard Christian buys 7,923 shares of HQL at $16.88; first position; stock 6.1% below 52-week high.

Pittard Christian, a director at abrdn Life Sciences Investors (HQL), initiated a new position by purchasing 7,923 shares at $16.88 on 2025-12-16, bringing his total holdings from 0 to 7,923 shares. The purchase price of $16.88 is positioned 1.21 basis points above the current price of $16.67 and $0.87 below the 52-week high of $17.75, placing the entry point near recent high-water marks. The fund's recent price momentum shows a 90-day gain of 18.4% offset by a 30-day decline of 3.4%, suggesting some volatility. This represents a first substantive position for this director and provides a factual data point on the timing and sizing of the initial accumulation decision; no prior trading record context is available to assess pattern.

Director Maher Bill purchases 650 shares of HQL at $15.37; holdings rise 61.0% to 1,715 shares

Director Maher Bill increased his stake in abrdn Life Sciences Investors (HQL) by purchasing 650 shares at $15.37 on 2024-08-23, expanding his total holdings by 61.0% from 1,065 to 1,715 shares. His prior buy at this ticker on 2023-12-28 realized a 90-day return of +0.6%, and that trade's timing pattern (90d return positive) indicates it was well-timed. Across his cross-ticker track record, he has made 11 prior buys with an 80.00% 90-day win rate and average 90-day return of +0.7%, though current market conditions show HQL down 3.6% from its 52-week high and -1.3% over the past 30 days. The significance of this buy is moderate: while it reflects continued accumulation in the same security and demonstrates a track record of positive longer-term outcomes on average, the recent price momentum is mixed and current valuation remains near mid-range within the 52-week band.

Director DiMartino Rose buys 1,000 shares of HQL at $15.53; first purchase in this holding.

DiMartino Rose purchased 1,000 shares at $15.53 on 2024-07-16, establishing an initial position in abrdn Life Sciences Investors. The purchase occurred near the 52-week high of $15.46, with the stock having gained 10.2% over 30 days and 17.7% over 90 days prior to the transaction. The insider's cross-ticker track record shows 3 prior buys, though no same-ticker history exists to assess prior patterns specific to HQL. The current price of $15.07 reflects a modest -2.5% decline from the 52-week high, indicating the stock has faced slight headwinds since the transaction date.

Saba Capital Management bought 100 shares of HQL at $14.07 on 2024-06-26, adding to 3.43M-share position

Saba Capital Management, a 10% owner of abrdn Life Sciences Investors (HQL), purchased 100 shares at $14.07 on 2024-06-26, a minor addition to its existing 3.43M-share holding. This is the fifth buy in a cluster of rapid consecutive purchases between 2024-06-10 and 2024-06-26, all at prices near the current $14.17 level. The stock has recovered 7.2% over 30 days and 4.0% over 90 days, and currently trades at -1.1% from its 52-week high of $14.33. Without measurable 90-day outcomes yet from the five recent transactions, and with no timing pattern established in the cross-ticker track record (20 prior buys), this filing reflects incremental accumulation at stable valuations rather than a signal of directional conviction or tactical repositioning.

10% Owner Saba Capital buys 13,812 HQL shares at $14.08, continuing series of 5 recent acquisitions in June 2024

Saba Capital Management accumulated 13,812 shares at $14.08 on 2024-06-24, the latest in a cluster of five consecutive daily purchases spanning 2024-06-07 through 2024-06-24. The aggregate buying activity increased the firm's HQL position from 3.42M to 3.43M shares (+0.4%). The current price of $14.18 stands near the 52-week high of $14.33, having appreciated 5.5% over the prior 30 days and 3.9% over 90 days. None of Saba's five most recent same-ticker transactions have yet reached 90-day measurement windows, so no prior outcome pattern at this ticker is available for comparison. The pattern reflects a sustained accumulation phase over a compressed timeframe in mid-to-late June.

Saba Capital buys 10,867 shares at $13.83 avg over 2 days; now holds 3.42M shares after 5 consecutive-day buying spree.

Saba Capital Management, a 10% owner of abrdn Life Sciences Investors (HQL), executed two purchases totaling 10,867 shares for $150,325.94 on June 12–13, 2024 at a blended average price of $13.83. This purchase added 0.3% to its post-transaction holding of 3,416,079 shares. The timing coincides with a recent buying pattern: the SAME-TICKER HISTORY shows five consecutive daily purchases at HQL from June 5–11, 2024, suggesting a deliberate accumulation sequence. The current stock price of $13.82 is -3.6% from the 52-week high and -3.1% over the prior 30 days, placing these purchases in a period of near-term price weakness. However, all five prior trades at this ticker remain unmeasurable at the 30-day and 90-day marks, so no outcome pattern yet exists for this ticker to assess timing accuracy of the recent activity.